1. Home
  2. POCI vs SCYX Comparison

POCI vs SCYX Comparison

Compare POCI & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precision Optics Corporation Inc.

POCI

Precision Optics Corporation Inc.

HOLD

Current Price

$4.40

Market Cap

34.7M

Sector

Health Care

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.78

Market Cap

32.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POCI
SCYX
Founded
1982
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.7M
32.6M
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
POCI
SCYX
Price
$4.40
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
35.3K
337.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,091,269.00
$257,000.00
Revenue This Year
N/A
$170.77
Revenue Next Year
N/A
$286.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.77
$0.57
52 Week High
$6.04
$1.29

Technical Indicators

Market Signals
Indicator
POCI
SCYX
Relative Strength Index (RSI) 37.48 54.78
Support Level $4.00 $0.77
Resistance Level $4.85 $0.88
Average True Range (ATR) 0.43 0.06
MACD -0.14 -0.00
Stochastic Oscillator 16.91 55.83

Price Performance

Historical Comparison
POCI
SCYX

About POCI Precision Optics Corporation Inc.

Precision Optics Corp Inc is engaged in designing, developing, and manufacturing advanced optical instruments. It manufactures medical products such as endoscopes and endocouplers which incorporate various optical technologies for use in a variety of minimally invasive surgical and diagnostic procedures. The company also produces endoscopes for various applications as well as designs and manufactures custom optical medical devices to satisfy customers' specific requirements. In addition, the company manufactures and sells components and assemblies specially designed for industrial and military use. The company earns the majority of its revenue from the United States.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: